| Primary |
| Product Used For Unknown Indication |
25.8% |
| Pneumonia Staphylococcal |
7.9% |
| Endocarditis |
6.7% |
| Pneumonia |
6.7% |
| Cardiac Failure |
4.5% |
| Cellulitis |
4.5% |
| Infection |
4.5% |
| Pulmonary Hypertension |
4.5% |
| Staphylococcal Infection |
4.5% |
| Antibiotic Prophylaxis |
3.4% |
| Immunosuppression |
3.4% |
| Pain |
3.4% |
| Paraspinal Abscess |
3.4% |
| Pyrexia |
3.4% |
| Anaemia |
2.2% |
| Antibiotic Resistant Staphylococcus Test Positive |
2.2% |
| Cardiac Disorder |
2.2% |
| Cardiac Failure Congestive |
2.2% |
| Nerve Block |
2.2% |
| Staphylococcal Sepsis |
2.2% |
|
| Drug Hypersensitivity |
11.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
11.4% |
| No Adverse Event |
11.4% |
| Death |
8.6% |
| Leukocytoclastic Vasculitis |
5.7% |
| Pain |
5.7% |
| Papule |
5.7% |
| Red Man Syndrome |
5.7% |
| Abdominal Discomfort |
2.9% |
| Abdominal Sepsis |
2.9% |
| Acute Myocardial Infarction |
2.9% |
| Anaemia |
2.9% |
| Bronchospasm |
2.9% |
| Cholangitis |
2.9% |
| Deafness |
2.9% |
| Drug Interaction |
2.9% |
| Drug Level Increased |
2.9% |
| Erythema |
2.9% |
| Face Oedema |
2.9% |
| Flushing |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
16.1% |
| Adult T-cell Lymphoma/leukaemia |
13.8% |
| Pulmonary Hypertension |
6.9% |
| Urinary Tract Infection |
6.1% |
| Osteitis |
5.7% |
| Staphylococcal Infection |
5.7% |
| Skin Ulcer |
5.4% |
| Anaemia |
4.6% |
| Cardiac Failure Congestive |
4.6% |
| Endocarditis |
4.6% |
| Antibiotic Therapy |
3.8% |
| Prophylaxis |
3.4% |
| Antifungal Prophylaxis |
2.7% |
| Meningitis |
2.7% |
| Pneumonia |
2.7% |
| Constipation |
2.3% |
| Life Support |
2.3% |
| Pneumonia Staphylococcal |
2.3% |
| Polyuria |
2.3% |
| Gastric Ulcer Haemorrhage |
1.9% |
|
| Urine Output Decreased |
12.8% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
10.6% |
| Toxic Epidermal Necrolysis |
8.5% |
| Tubulointerstitial Nephritis |
8.5% |
| Drug Hypersensitivity |
6.4% |
| Renal Disorder |
6.4% |
| Drug Effect Decreased |
4.3% |
| Face Oedema |
4.3% |
| Hepatic Function Abnormal |
4.3% |
| Hepatocellular Injury |
4.3% |
| Human Herpes Virus 6 Serology Positive |
4.3% |
| Interstitial Lung Disease |
4.3% |
| Leukopenia |
4.3% |
| Septic Shock |
4.3% |
| Acute Generalised Exanthematous Pustulosis |
2.1% |
| Acute Respiratory Distress Syndrome |
2.1% |
| Anaemia |
2.1% |
| Aphasia |
2.1% |
| Back Pain |
2.1% |
| Basedow's Disease |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.9% |
| Infection Prophylaxis |
13.7% |
| Prophylaxis |
9.4% |
| Prophylaxis Against Graft Versus Host Disease |
6.8% |
| Bone Marrow Conditioning Regimen |
6.4% |
| Sepsis |
3.5% |
| Acute Myeloid Leukaemia |
3.3% |
| Antifungal Prophylaxis |
3.0% |
| Premedication |
2.6% |
| Acute Lymphocytic Leukaemia |
2.6% |
| Electrolyte Substitution Therapy |
2.4% |
| Pain |
2.2% |
| Hypertension |
2.1% |
| Antibiotic Prophylaxis |
2.0% |
| Interstitial Lung Disease |
2.0% |
| Febrile Neutropenia |
1.8% |
| Constipation |
1.7% |
| Graft Versus Host Disease |
1.7% |
| Cardiac Failure |
1.5% |
| Disseminated Intravascular Coagulation |
1.4% |
|
| Acute Graft Versus Host Disease In Skin |
7.8% |
| Gastrointestinal Perforation |
7.8% |
| Hepatic Infection Fungal |
7.8% |
| Hypokalaemia |
7.8% |
| White Blood Cell Count Decreased |
7.8% |
| Vomiting |
5.9% |
| Anuria |
3.9% |
| Bacterial Sepsis |
3.9% |
| Cardiac Failure Congestive |
3.9% |
| Cardiomyopathy |
3.9% |
| Colitis |
3.9% |
| Crohn's Disease |
3.9% |
| Cystitis Haemorrhagic |
3.9% |
| Decreased Appetite |
3.9% |
| Disseminated Intravascular Coagulation |
3.9% |
| Engraft Failure |
3.9% |
| Hypertension |
3.9% |
| Injury |
3.9% |
| Pneumonia |
3.9% |
| Pneumonia Cytomegaloviral |
3.9% |
|
| Interacting |
| Localised Infection |
22.2% |
| Subcutaneous Abscess |
22.2% |
| Wound Infection |
22.2% |
| Depression |
11.1% |
| Restless Legs Syndrome |
11.1% |
| Sleep Disorder |
11.1% |
|
| Drug Interaction |
42.9% |
| Nephropathy Toxic |
28.6% |
| Hypokalaemia |
14.3% |
| Staphylococcal Infection |
14.3% |
|
